The Moderate To Severe Acute Pain Market Size in the 7MM was valued at ~USD 4,536 million in 2025 and is projected to reach USD 13,579 million in 2034 at a CAGR of 13.00%, estimates DelveInsight

DelveInsight's "Moderate To Severe Acute Pain Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Moderate To Severe Acute Pain, historical and forecasted epidemiology as well as the Moderate To Severe Acute Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Moderate To Severe Acute Pain Market Share @ Moderate To Severe Acute Pain Market Outlook- https://www.delveinsight.com/sample-request/moderate-to-severe-acute-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Moderate To Severe Acute Pain Market Report
• In the 7MM, the US accounted for the highest number of incident cases of acute pain, with nearly 86,800,000 cases in 2024.
• Among the 7MM, the US captured the highest Moderate to Severe Acute Pain Market in 2024, covering nearly USD 3,500 million, followed by Germany, which is anticipated to grow during the forecast period (2025-2034).
• In 2024, EU4 and the UK captured nearly 15% of the Moderate to Severe Acute Pain Market in the 7MM.
• Among EU4 and the UK, the maximum cases were reported in Germany, followed by France, and the least cases were found in Spain.
• In the US, about 40% of cases observed were of moderate acute pain, and 20% for severe acute pain.
• In the UK, approximately 4,417,000 cases of trauma pain, 3,492,000 cases of postoperative pain, and 3,306,000 cases of acute medical illness in 2024.
• Japan accounted for about 8,419,000 cases of moderate acute pain and about 2,078,000 cases of severe acute pain, in 2024.
• The leading Moderate To Severe Acute Pain Companies such as QRxPharma Inc., Talphera Inc., Scilex Pharmaceuticals Inc., Mundipharma SAS and others.
• Promising Moderate To Severe Acute Pain Pipeline Therapies such as Q8003, Sufentanil Sublingual tablet 30 mcg, ZalvisoTM 15 mcg, Morphine sulfate, Oxycodone HCl, SP-103, and others.

Stay ahead in the Moderate To Severe Acute Pain Therapeutics Market with DelveInsight's Strategic Report @ Moderate To Severe Acute Pain Market Outlook- https://www.delveinsight.com/sample-request/moderate-to-severe-acute-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Moderate To Severe Acute Pain Epidemiology Segmentation in the 7MM
• Total Incident Cases of Acute Pain
• Total Diagnosed Incident Cases of Acute Pain
• Severity-specific Diagnosed Incident Cases of Acute Pain

Download the report to understand which factors are driving Moderate To Severe Acute Pain Epidemiology Trends @ Moderate To Severe Acute Pain Prevalence- https://www.delveinsight.com/sample-request/moderate-to-severe-acute-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Moderate-to-Severe Acute Pain Marketed Drugs
• JOURNAVX: Vertex Pharmaceuticals
JOURNAVX (formally known as VX-548) is a first-in-class, oral, nonopioid, highly selective pain signal inhibitor that is selective for NaV1.8 relative to other NaV channels. Because JOURNAVX blocks pain signals only found in the periphery, not in the brain, JOURNAVX provides effective relief of pain without the limitations of currently available therapies, including the addictive potential of opioids.

• ATZUMI (dihydroergotamine): Satsuma Pharmaceuticals
ATZUMI (dihydroergotamine) nasal powder is the first and only DHE nasal powder indicated for the acute treatment of migraine with or without aura in adults, delivered through a convenient, portable device. It is also the first and only product to utilize the proprietary SMART (Simple MucoAdhesive Release Technology) platform, which combines advanced powder formulation with innovative device technology to enable simplified and effective intranasal delivery of dihydroergotamine.

Moderate To Severe Acute Pain Emerging Drugs
• mdc-CWM (F14): MedinCell/Arthritis Innovation Corporation (AIC)
F14 is a sustained-release formulation of the NSAID, celecoxib, designed to reduce pain and inflammation and enhance recovery after TKR. mdc-CWM is administered into the intra-articular space at the end of TKR surgery and may provide pain relief over several weeks post-surgery. The drug is currently being evaluated in the Phase III trial for the pain management of total knee replacement.

• LTG-001: Latigo Biotherapeutics
LTG-001 is an oral, investigational selective inhibitor of Nav1.8, a key sodium channel involved in pain signaling. LTG-001 works by blocking peripheral sensory neurons responsible for pain signals, thus preventing the transmission of these pain signals to the central nervous system. As a result, LTG-001 may provide effective pain relief without the risks associated with opioids.

• Cebranopadol: Tris Pharma
Cebranopadol is a first-in-class investigational therapy that targets two key receptors, the Nociceptin/Orphanin FQ Peptide (NOP) and μ-opioid Peptide (MOP) receptors (a dual-NMR agonist), for the treatment of moderate-to-severe pain, as well as Opioid Use Disorder. These receptors are partially homologous to each other, and they play both complementary and distinct roles to modulate pain biology pathways.

Moderate To Severe Acute Pain Treatment Market Landscape
The Moderate To Severe Acute Pain treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Moderate To Severe Acute Pain has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Moderate To Severe Acute Pain treatment guidelines, visit @ Moderate To Severe Acute Pain Treatment Market Landscape- https://www.delveinsight.com/sample-request/moderate-to-severe-acute-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Moderate To Severe Acute Pain Market Outlook
The current Moderate to Severe Acute Pain treatment approach consists of various methods, which are divided into pharmacological and non-pharmacological therapies. Pharmacological treatments include analgesics, which are further categorized into opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, corticosteroids, anesthetics, and more. Acute pain is also addressed with benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, gamma-aminobutyric acid (GABA) agonists, and cannabinoids. The Moderate To Severe Acute Pain Market is expected to experience positive growth with the approval of potential Moderate To Severe Acute Pain drugs like mdc-CWM (F14), OCS-01, MR-301, TK-254Rx, DEPADE, and others.

Moderate To Severe Acute Pain Drugs Uptake
The drug chapter of the Moderate To Severe Acute Pain report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Moderate To Severe Acute Pain.

Major Moderate To Severe Acute Pain Companies
QRxPharma Inc., Talphera Inc., Scilex Pharmaceuticals Inc., Mundipharma SAS and others.

Learn more about the FDA-approved drugs for Moderate To Severe Acute Pain @ Drugs for Moderate To Severe Acute Pain Treatment- https://www.delveinsight.com/sample-request/moderate-to-severe-acute-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Moderate To Severe Acute Pain Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Moderate To Severe Acute Pain Companies- QRxPharma Inc., Talphera Inc., Scilex Pharmaceuticals Inc., Mundipharma SAS and others.
• Moderate To Severe Acute Pain Pipeline Therapies- Q8003, Sufentanil Sublingual tablet 30 mcg, ZalvisoTM 15 mcg, Morphine sulfate, Oxycodone HCl, SP-103, and others.
• Moderate To Severe Acute Pain Market Dynamics: Moderate To Severe Acute Pain Market Drivers and Barriers
• Moderate To Severe Acute Pain Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Moderate To Severe Acute Pain Drugs in development @ Moderate To Severe Acute Pain Clinical Trials Assessment- https://www.delveinsight.com/sample-request/moderate-to-severe-acute-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Moderate To Severe Acute Pain Executive Summary
3. Competitive Intelligence Analysis for Moderate To Severe Acute Pain
4. Moderate To Severe Acute Pain: Market Overview at a Glance
5. Moderate To Severe Acute Pain: Disease Background and Overview
6. Patient Journey
7. Moderate To Severe Acute Pain Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Moderate To Severe Acute Pain Unmet Needs
10. Key Endpoints of Moderate To Severe Acute Pain Treatment
11. Moderate To Severe Acute Pain Marketed Products
12. Moderate To Severe Acute Pain Emerging Therapies
13. Moderate To Severe Acute Pain: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Moderate To Severe Acute Pain Market Outlook
16. Access and Reimbursement Overview of Moderate To Severe Acute Pain
17. KOL Views
18. Moderate To Severe Acute Pain Market Drivers
19. Moderate To Severe Acute Pain Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.